Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bexobrutideg + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Nurix Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
NX-5948 + obinutuzumab is an investigational drug combination consisting of bexobrutideg (NX-5948), an oral, brain-penetrant, highly selective small-molecule degrader of Bruton's tyrosine kinase (BTK), and obinutuzumab (Gazyva), an approved glycoengineered, type II anti-CD20 monoclonal antibody. Bexobrutideg functions as a proteolysis-targeting chimera (PROTAC) that recruits the cereblon (CRBN) E3 ubiquitin ligase complex to induce the ubiquitination and subsequent proteasomal degradation of both wild-type and mutated forms of BTK, thereby overcoming resistance to conventional BTK inhibitors. Obinutuzumab targets CD20 on B cells, inducing direct cell death and enhancing antibody-dependent cellular cytotoxicity (ADCC). The combination is being co-developed by Nurix Therapeutics and Roche and is currently in Phase 1b/2 clinical trials for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Other names
- NX-5948 + obinutuzumabbexobrutideg + obinutuzumabobinutuzumab + NX-5948obinutuzumab + bexobrutideg
02
Targets
Beyond the preview
Go deeper on bexobrutideg + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bexobrutideg + obinutuzumab.